EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor‐Associated Musculoskeletal Symptoms in Breast Cancer

Nicole M G Fleege iD, Elise A Miller, Kelley M Kidwell, Zeb R Zacharias, Jon Houtman iD, Kelly Scheu, Kathleen Kemmer, Kevin F Boehnke, N Lynn Henry iD

Cancer Medicine · 2025-08 · 14 (15)

DOI: 10.1002/cam4.71117 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, online erschienen am 01.08.2025. Verfasst von Nicole M G Fleege und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Breast Neoplasms, Cannabidiol, Musculoskeletal Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, Rising Tide Foundation for Clinical Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Aromatase inhibitor (AI) therapy reduces breast cancer recurrence risk. However, some patients stop treatment early because of AI‐associated musculoskeletal symptoms (AIMSS). AIMSS is due in part to systemic inflammation. Cannabidiol (CBD) has anti‐nociceptive and anti‐inflammatory properties, making it a potential treatment option for AIMSS.

Methods

Women with stage 0–3 hormone receptor‐positive breast cancer experiencing AIMSS enrolled in this phase 2 clinical trial. Patients received CBD (Epidiolex), titrated over 4 weeks to 100 mg BID, for a total of 15 weeks. Patient‐reported outcomes were collected serially. The primary endpoint was the number of patients with at least a 2‐point reduction in worst pain from baseline to 15 weeks. Statistical analysis was completed using paired t ‐tests and linear mixed models.

Results

Of 39 eligible patients, 28 completed protocol‐directed study treatment. Eleven discontinued treatment due to toxicity ( n = 5) or per patient preference ( n = 6). Seventeen of 39 patients met the primary endpoint (43.6%, 95% CI [28%, 60%]). Worst pain improved 0.13 per week of treatment ( p < 0.001) for all patients; average improvement in worst pain was 1.95 points at the end of 15 weeks. Of the 28 patients who completed the study, average reduction in worst pain was 2.36 points (95% CI [−3.22, −1.49]) between baseline and Week 15.

Conclusion

Treatment with CBD was safe, tolerable, and associated with improvement in joint pain for a subset of patients. Additional studies are needed to further understand the impact of CBD on AIMSS and which patients are most likely to benefit from CBD treatment. Trial Registration www.clinicaltrials.gov : NCT04754399

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aromatase InhibitorsBreast NeoplasmsCannabidiolMusculoskeletal DiseasesHumansFemalePilot ProjectsMiddle AgedAgedAdultPatient Reported Outcome MeasuresTreatment Outcome

Stichwörter der Autor:innen

aromatase inhibitor associated musculoskeletal symptomsbreast cancercannabidiolcannabisclinical trialendocrine therapyquality of lifesupportive care

Substanzen

Aromatase InhibitorsCannabidiol

Autor:innen und Institutionen

  • University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
  • Human Immunology Core, Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.

ORCID-Profile: Nicole M G Fleege, Jon Houtman, N Lynn Henry

Förderung

  • NCATS NIH HHS
  • NIH HHS
  • Rising Tide Foundation for Clinical Cancer Research
  • Conquer Cancer Foundation
  • National Institutes of Health

Zitieren

APA

Fleege, N. M. G., Miller, E. A., Kidwell, K. M., Zacharias, Z. R., Houtman, J., Scheu, K., Kemmer, K., Boehnke, K. F., & Henry, N. L. (2025). Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor‐Associated Musculoskeletal Symptoms in Breast Cancer. Cancer Medicine, 14(15). https://doi.org/10.1002/cam4.71117

Vancouver

Fleege NMG, Miller EA, Kidwell KM, Zacharias ZR, Houtman J, Scheu K, et al. Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor‐Associated Musculoskeletal Symptoms in Breast Cancer. Cancer Medicine. 2025;14(15). doi:10.1002/cam4.71117

BibTeX
@article{Fleege2025,
  author = {Fleege, Nicole M G and Miller, Elise A and Kidwell, Kelley M and Zacharias, Zeb R and Houtman, Jon and Scheu, Kelly and Kemmer, Kathleen and Boehnke, Kevin F and Henry, N Lynn},
  title = {Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor‐Associated Musculoskeletal Symptoms in Breast Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {15},
  doi = {10.1002/cam4.71117}
}
Kostenlos starten →